Advertisement

Pneumocystis jiroveci Pneumonia Without Failure to Thrive

  • Mihaela Tatiana Bataneant
  • Patricia Urtila
Chapter

Abstract

  • A normal development and lymphocyte count do not exclude a combined immunodeficiency

  • All males with Pneumocystis jirovecii pneumonia, hypogammaglobulinemia with normal IgM must be tested for CD40L deficiency

  • Allogeneic hematopoietic stem cell transplantation is the only curative treatment currently available in CD40L deficiency and must be performed prior to the onset of a life-threatening complication and end organ damage

Keywords

Pneumocystis jirovecii pneumonia CD40L deficiency Hematopoietic stem cell transplantation 

References

  1. 1.
    Subbarayan A, Colarusso G, Hughes SM, Gennery AR, Slatter M, Cant AJ, Arkwright PD. Clinical features that identify children with primary immunodeficiency diseases. Pediatrics. 2011;127(5):810–6.CrossRefGoogle Scholar
  2. 2.
    Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol. 2013;55(1):49–58.CrossRefGoogle Scholar
  3. 3.
    Arkwright PD, Gennery AR. Ten warning signs of primary immunodeficiency: a new paradigm is needed for the 21st century. Ann N Y Acad Sci. 2011;1238:7–14.CrossRefGoogle Scholar
  4. 4.
    Buckley RH, Schiff RI, Schiff SE, Markert ML, Williams LW, Harville TO, Roberts JL, Puck JM. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130(3):378–87.CrossRefGoogle Scholar
  5. 5.
    Conley ME, Buckley RH, Hong R, Guerra-Hanson C, Roifman CM, Brochstein JA, Pahwa S, Puck JM. X-linked severe combined immunodeficiency. Diagnosis in males with sporadic severe combined immunodeficiency and clarification of clinical findings. J Clin Invest. 1990;85(5):1548–54.CrossRefGoogle Scholar
  6. 6.
    Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bordigoni P, Resnick I, Fasth A, Baer M, Gomez L, Sanders EA, Tabone MD, Plantaz D, Etzioni A, Monafo V, Abinun M, Hammarstrom L, Abrahamsen T, Jones A, Finn A, Klemola T, DeVries E, Sanal O, Peitsch MC, Notarangelo LD. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131(1 Pt 1):47–54.CrossRefGoogle Scholar
  7. 7.
    Lee WI, Torgerson TR, Schumacher MJ, Yel L, Zhu Q, Ochs HD. Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood. 2005;105(5):1881–90.CrossRefGoogle Scholar
  8. 8.
    Winkelstein JA, Marino MC, Ochs H, Fuleihan R, Scholl PR, Geha R, Stiehm ER, Conley ME. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine. 2003;82(6):373–84.CrossRefGoogle Scholar
  9. 9.
    Gilmour KC, Walshe D, Heath S, Monaghan G, Loughlin S, Lester T, Norbury G, Cale CM. Immunological and genetic analysis of 65 patients with a clinical suspicion of X linked hyper-IgM. Mol Pathol. 2003;56(5):256–62.CrossRefGoogle Scholar
  10. 10.
    Hollenbaugh D, Wu LH, Ochs HD, Nonoyama S, Grosmaire LS, Ledbetter JA, Noelle RJ, Hill H, Aruffo A. The random inactivation of the X chromosome carrying the defective gene responsible for X-linked hyper IgM syndrome (X-HIM) in female carriers of HIGM1. J Clin Invest. 1994;94(2):616–22.CrossRefGoogle Scholar
  11. 11.
    Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ, Stamenkovic I, Ledbetter JA, Aruffo A. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 1992;11(12):4313–21.CrossRefGoogle Scholar
  12. 12.
    Hayward AR, Levy J, Facchetti F, Notarangelo L, Ochs HD, Etzioni A, Bonnefoy JY, Cosyns M, Weinberg A. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol. 1997;158(2):977–83.PubMedGoogle Scholar
  13. 13.
    Gennery AR, Khawaja K, Veys P, Bredius RG, Notarangelo LD, Mazzolari E, Fischer A, Landais P, Cavazzana-Calvo M, Friedrich W, Fasth A, Wulffraat NM, Matthes-Martin S, Bensoussan D, Bordigoni P, Lange A, Pagliuca A, Andolina M, Cant AJ, Davies EG. Treatment of CD40 ligand deficiency by hematopoietic stem cell transplantation: a survey of the European experience, 1993-2002. Blood. 2004;103(3):1152–7.CrossRefGoogle Scholar
  14. 14.
    Tomizawa D, Imai K, Ito S, Kajiwara M, Minegishi Y, Nagasawa M, Morio T, Nonoyama S, Mizutani S. Allogeneic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience. Am J Hematol. 2004;76(1):33–9.CrossRefGoogle Scholar
  15. 15.
    Tsuji Y, Imai K, Kajiwara M, Aoki Y, Isoda T, Tomizawa D, Imai M, Ito S, Maeda H, Minegishi Y, Ohkawa H, Yata J, Sasaki N, Kogawa K, Nagasawa M, Morio T, Nonoyama S, Mizutani S. Hematopoietic stem cell transplantation for 30 patients with primary immunodeficiency diseases: 20 years experience of a single team. Bone Marrow Transplant. 2006;37(5):469–77.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Mihaela Tatiana Bataneant
    • 1
    • 2
  • Patricia Urtila
    • 1
    • 2
  1. 1.“Victor Babes” University of Medicine and PharmacyTimisoaraRomania
  2. 2.“Louis Turcanu” Children’s Emergency Clinical HospitalTimisoaraRomania

Personalised recommendations